Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

* Subject must be ≥ 18 years of age with life expectancy \> 12 weeks. * Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers. * Subject must have NSCLC that is not amenable to surgical resection or radiation with curative intent at time of screening. * Subject must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

* Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor). * Subject has a known hypersensitivity to platinum compounds. * Subject has peripheral neuropathy ≥ grade 2. * Subject has squamous NSCLC, or an untreated known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic lymphoma kinase (ALK) gene rearrangement. * Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.